Grants

Washington State Recreation and Conservation Office

Funding supports acquisition, development, planning of nonmotorized recreation opportunities.

Up to $200K

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nonhighway and Off-Road Vehicle Activities Program - Off-Road Vehicle

Washington State Recreation and Conservation Office

Funding supports acquisition, development, planning of ORV recreation opportunities.

Up to $200K

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nonhighway and Off-Road Vehicle Activities Program - Off-Road Vehicle

Washington State Recreation and Conservation Office

Funding supports acquisition, development, planning of ORV recreation opportunities.

Up to $200K

Free to search & build · $99 one-time to unlock the application pack · No subscription

Noninvasive Neuromodulation to Improve Hand Motor Function in Multiple Sclerosis

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

Project Summary/Abstract Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects nearly one million Americans. Although more than 75% of persons with MS (PwMS) experience hand motor impairments that reduce independence and quality of life, current treatments primarily aim to slow disease progression through pharmacological approaches and rehabilitation and often do not improve motor function. Recent evidence shows that reduced corticospinal transmission is strongly associated with motor impairment severity in PwMS, highlighting the need for targeted strategies to strengthen residual corticospinal pathways. Therefore, this project aims to evaluate the therapeutic potential of paired corticospinal-motoneuronal stimulation (PCMS) in improving hand dexterity in PwMS. PCMS, a noninvasive mechanism-driven neuromodulation approach, enhances corticospinal transmission by producing long-term potentiation-like effects at the corticospinal-motoneuronal synapse by precisely pairing transcranial magnetic stimulation (TMS) with peripheral nerve stimulation (PNS). This project first aims to examine the effects of a single PCMS session on corticospinal transmission and hand motor function in PwMS. Using a randomized, crossover design, 25 PwMS will complete two sessions: (1) PCMS and (2) sham-PCMS. Each session will deliver 180 paired TMS-PNS stimuli over 30 minutes. The primary outcome is performance on the 9-Hole Peg Test (9HPT). Secondary outcomes include pinch grip force, maximal voluntary contraction (MVC), MEP amplitude and latency, F-wave parameters, and M- max amplitude. It is hypothesized that PCMS will enhance corticospinal transmission and improve hand motor performance compared to sham stimulation. Second, this project will examine the effects of PCMS combined with hand motor training in PwMS. Forty-eight PwMS will be randomized to receive either PCMS or sham-PCMS combined with motor training over 10 sessions in 3–4 weeks. Outcomes will be assessed at baseline, post- intervention, and one-month follow-up. It is hypothesized that PCMS participants receiving PCMS with motor training to show greater functional gains than those receiving sham-PCMS with motor training and the functional gains will be better maintained in the PCMS with motor training group at follow-up. This project is the first to apply PCMS in PwMS, leveraging a noninvasive neuromodulation strategy to specifically enhance corticospinal output for improving manual dexterity. Findings will establish proof-of-concept for this intervention in PwMS and guide future studies optimizing stimulation protocols and evaluating clinical efficacy on a larger scale. Ultimately, this work may lead to a new therapeutic approach to improve dexterity, independence, and quality of life for people living with MS.

Up to $426K

2028-05-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nonpeptidergic neurons suppress cutaneous inflammation via glutamate release

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY/ABSTRACT Rosacea is an inflammatory disorder of the skin that manifests with chronic symptoms including pruritus (itch), rash, and flushing and contributes significantly to patient morbidity. The prevalence of rosacea is estimated to be as high as 20% in some populations. Mast cell activation and degranulation is a key mediator of rosacea symptoms. A growing body of evidence has demonstrated that cutaneous sensory neurons and skin-resident immune cells including mast cells work synergistically to promote local inflammation. For example, pain sensing Trpv1-expressing neurons release the neuropeptide Substance P which activates dermal mast cells via the MrgprB2 receptor. Our recent work has explored the role of a distinct subset of sensory neurons innervating the epidermis, classified as nonpeptidergic type 1 neurons (NP1). In contrast to the mast cell activating capacity of Trpv1 neurons, NP1 neurons suppress mast cell function through the release of the neurotransmitter glutamate which acts directly on mast cells via the kainate receptor GluK2. We have recently found that β-alanine, a known ligand of the NP1 mas related G-protein-coupled receptor D (Mrgprd) that triggers glutamate release, and the small molecule GluK2 receptor agonist SYM2081 both suppressed mast cell-induced inflammation in models of rosacea. Remarkably, in preliminary clinical studies, we have discovered that topical administration of β-alanine suppresses rosacea flushing. Thus, we have discovered a novel neuron-mast cell circuit that regulates cutaneous inflammation. Upon further investigation of this pathway, we have found that abrogation of glutamate release from NP1 neurons augments clearance of epicutaneous Candida albicans infection (a model that is generally thought to be dependent on T cells and not mast cells). Conversely topical SYM2081 treatment induces broad transcriptional changes in multiple immune subsets in the skin. Taken together, our data predicts that NP1-derived glutamate, through its action on mast cells, has broader effects on cutaneous immunity than previously appreciated. We hypothesize that NP1-neuron derived glutamate regulates the responsiveness of mast cells at steady state which subsequently determines the composition of immune cells and functional immune responses in the skin. This proposal will investigate this pathway using transgenic mice that enable us to simulate conditions of low glutamate via the conditional ablation of glutamate release from NP1 neurons (Aim 1) as well as conditions of increased glutamate using direct small molecule agonism of the GluK2 receptor on mast cells (Aim 2). Findings from these studies will provide a mechanistic understanding of how NP1 neurons regulate immunity in the skin. Data generated from this study will have direct clinically translational impact in the treatment of rosacea and other cutaneous inflammatory processes. Contribution to Training: This proposal combines rigorous training in neurogenic inflammation and clinical medicine which will greatly enhance my ability to develop into a highly productive academic physician-scientist.

Up to $55K

2030-03-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nonterminal Albumin Fusions for Improved Delivery of Polypeptides

NIBIB - National Institute of Biomedical Imaging and Bioengineering

PROJECT SUMMARY/ABSTRACT Polypeptides, due to their high affinity and selectivity for diverse biological targets, hold significant promise as therapeutic agents for treating complex diseases such as cancer, metabolic disorders, and infectious diseases. However, poor pharmacokinetics (PK), including rapid renal clearance and protease degradation, often hinders their clinical applications. This leads to short half-lives and limited bioavailability, necessitating frequent dosing and increasing the burden on the patient and the risk of side effects. Existing strategies to improve PK, such as recombinant fusions to the N- or C-terminus of human serum albumin (HSA) or chemical modifications to constrain conformation like cyclization, frequently compromise the biological activity and manufacturability of these therapeutic agents. This project aims to avoid activity losses due to the steric hindrance from the albumin fusion partner while constraining conformation naturally by developing a novel platform that nonterminally fuses polypeptides to albumin. Nonterminal fusions are relatively unexplored due to the challenges associated with maintaining the native folding and function of the fusion partner. However, recent advancements in structural prediction tools now enable us to accurately predict and mitigate these disruptions. We hypothesize that nonterminally fusing polypeptide cargoes to albumin at externally presented disulfide-constrained loop regions will significantly improve their pharmacokinetic properties without compromising their activity. We will evaluate this strategy for the ability to enhance the stability, half-life, and target localization of therapeutic polypeptides through three specific aims: Aim 1 will establish an expression system and leverage a model peptide to screen potential insertion sites for structural perturbations and availability. Aim 2 will use AlphaFold to develop a computational pipeline to predict structural changes due to nonterminal fusions, establishing rules for generalizing the strategy to any payload. Aim 3 will evaluate the PK properties and therapeutic benefits of nonterminal fusions of Neo-2/15, an engineered IL-2/15 receptor agonist, in cancer models. Successful completion of this project will yield a robust platform for nonterminally fusing polypeptides to albumin, offering a modular and generalizable strategy to improve drug activity, half-life, and target tropism. This approach has the potential to significantly advance the fields of protein engineering and drug delivery. By establishing a precedent and pipeline for nonterminal fusions across any carrier proteins, more effective and durable treatments can be developed in many therapeutic areas and indications, ultimately improving patient outcomes and enhancing public health.

Up to $46K

2028-04-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

Norad Civil Society Grant Scheme

Norwegian Agency for Development Cooperation (Norad)

Supports civil society organizations in developing countries working on democratic governance, human rights, and climate and environment. Multi-year framework agreements.

$100K – $5M

governancehuman rightsclimate+1

Free to search & build · $99 one-time to unlock the application pack · No subscription

Norad Knowledge Bank Programme

Norwegian Agency for Development Cooperation (Norad)

Funds knowledge exchange and institutional partnerships between Norwegian and developing-country institutions. Supports research, education, and professional development.

$50K – $2M

Educationresearchinstitutional development

Free to search & build · $99 one-time to unlock the application pack · No subscription

Noradrenergic mechanisms underlying stress-induced opioid reinstatement

NIDA - National Institute on Drug Abuse

PROJECT SUMMARY The initiating factor for opioid use disorder often stems from comorbid neuropsychiatric conditions including anxiety, depression, and post-traumatic stress disorder. Experience of extreme or traumatic stress is often the underlying factor responsible for these neuropsychiatric conditions and, thus, investigation into the neural mechanisms by which stress impacts the brain is essential for determining the mechanisms responsible for the initiation of substance use disorders. Our preliminary data demonstrates that stress exposure leads to increased cytokine release and heightened activity of the noradrenergic locus coeruleus (LC), a key region responsible for the integration of stress signaling that projects norepinephrine to numerous downstream brain areas. The prelimbic cortex of the medial prefrontal cortex (PrL) is one such region that receives over 90% of its noradrenergic innervation from the LC and plays a major role in drug seeking and reward-related behaviors. Thus, the overall goal of this project is to establish the circuit mechanisms of stress-related norepinephrine release in the PrL and the role of these projections in oral oxycodone seeking behaviors. These experiments will use cutting edge techniques including chemogenetics, in vivo electrophysiology, and fiber photometry with GRAB sensors to monitor neuronal activity and transmitter release across this circuit in response to stress and drug stimuli. Three main experiments have been designed to address the hypothesis that stress-evoked increases in neuroimmune activity in the LC initiate neuronal activation and downstream NE release to mediate stress- induced drug seeking behavior. First, chemogenetic suppression of neuroimmune activity in the LC will be paired with in vivo electrophysiology during stress to monitor the impact of microglial reactivity on neuronal activity within this region (Aim1, K99). The second experiment will utilize GRABNE sensors in the PrL to determine the time-course of norepinephrine release in response to stress cues. These studies will also use adrenergic receptor antagonists microinjected into the PrL during stress-cue reinstatement to determine the mechanisms by which NE is acting in this region to impact drug seeking behaviors (Aim2, K99). The final experiment will use translationally relevant compounds to determine if the reversal of stress-induced neuroimmune reactivity can prevent the deleterious effects observed as a consequence of stress (Aim3, R00). Taken together, these studies will expand our understanding of the circuit mechanisms responsible for stress-related opioid seeking behaviors and determine the therapeutic potential of clinically available pharmaceuticals all while providing extensive training in innovative preclinical techniques. The combined technical training and career development opportunities supported by this application will facilitate further independent projects designed to address unanswered questions regarding the neural mechanisms responsible for opioid use to develop novel treatment targets for comorbid stress and substance use disorders.

Up to $192K

2028-01-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Noradrenergic modulation of cortical taste processing

NIDCD - National Institute on Deafness and Other Communication Disorders

PROJECT SUMMARY Neuromodulators play a critical role in adaptively regulating sensory neural computations, yet their effects on the taste system remain poorly understood. The gustatory cortex (GC), a subregion of the insular cortex, receives a prominent modulatory input from norepinephrine (NE)-producing neurons in the locus coeruleus (LC). Despite this anatomical connection, the functional role of the LC-GC pathway has not been investigated. Our long-term goal is to understand how LC-NE dynamics influence taste perception by modulating taste encoding in the GC. Previous research in rodents has shown that GC ensemble activity encodes taste identity and palatability in a sequential manner within approximately 2.5 seconds of taste reception. Building on these findings, we hypothesize that the timing of LC-NE activation relative to tastant reception significantly shapes its effects on the encoding of taste identity and palatability. To test this hypothesis, we propose three synergistic research aims. In Aim 1, we will characterize the patterns of LC-NE activity in the context of tasting. We will examine how these patterns are influenced by taste valence, expectedness, and the acquisition of cue-taste associations. Specifically, using fiber photometry, we will monitor LC calcium dynamics and NE release in the GC as mice anticipate and sample intraorally delivered tastants. In Aim 2, we will determine the causal impact of LC-NE activity on GC taste encoding by manipulating LC output with temporal precision. We will use optogenetic tools to activate or inhibit LC axons in the GC, in combination with miniscope calcium imaging. This will allow us to assess how the timing of LC input influences GC neuronal responses and the ensemble representation of taste identity and palatability. In Aim 3, we will investigate the role of the LC-GC pathway in shaping taste-guided behaviors. We will assess taste discrimination using a two-alternative choice task and measuring taste palatability perception through licking behavior and orofacial responses. Together, these studies will provide a comprehensive understanding of how behavioral demands modulate LC activity to shape taste encoding and perception. The insights gained may advance our understanding of the neural regulation of adaptive and maladaptive consummatory behaviors.

Up to $565K

2031-03-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nordstrom Foundation Grants

Nordstrom Foundation

Supports youth empowerment, workforce development, and equity-focused programs.

$10K – $250K

youth developmentworkforce developmentequity

Free to search & build · $99 one-time to unlock the application pack · No subscription

Normal and Pathological Musculoskeletal Loss and Repair

NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases

Project Summary The purpose of this ‘A1 Single-Year NIAMS/NCI R13 Research Conference Grant’ is to host the highest impact scientific and mentoring conference on “Bone: Musculoskeletal Tumor Perspectives’ that will bring together translational and clinical investigators from diverse specialties. Musculoskeletal Tumor Society (MSTS) is the primary host organization that will partner with OREF, ORS, AAOS, and JOR. Musculoskeletal Oncology is a distinct hybrid clinical and research field that requires the solution to 3 distinct problems: ‘Diagnosing’ and ‘Treating’ molecular oncogenesis of MSK tissues and ‘Reconstructing’ afflicted tissue structures to restore limb function. Due to underlying oncological pathophysiology and massive skeletal defects, traditional orthopaedic treatments using trauma or arthroplasty disciplines were associated with high rate of complications. Furthermore, no cross-disciplinary research and mentoring endeavors on bone tumors have not been offered. Many bone and osteoclast-associated molecules were discovered from bone diseases and tumors such as the giant cell tumor of bone. The last AAOS-initiated R13 Conference was in 2017. There is a serious issue of discontinuation of clinician scientists and basic scientists who conduct cross-disciplinary research on bone and reconstruction science from a perspective of musculoskeletal tumors. There is an urgent need to host a R13 conference to offer mentorship for emerging investigators and to develop new collaborations. Our innovative meeting format features sessions addressing challenging clinical problems with plenary overview talks by experts on state-of the art techniques (spatial biology, artificial intelligence, novel signaling & targeted therapies, novel skeletal stem cells, RNA/DNA therapeutics, 3D printed custom device, and mixed reality). We will invite junior surgeon-scientists to present their innovative solutions in mentoring sessions where a panel of established investigators will critique proposed strategies and Specific Aims in a live multi-disciplinary “study section”. ESI selection criteria are based on one-page Specific Aims that summarizes clinical barriers, hypothesis-/technology-driven scientific and clinical investigation plans, and specific needs for mentorship. A meet-the-mentors session will be set up to foster multi-disciplinary collaboration among mentors and emerging surgeon-scientists, engineers, and basic scientists. In order to facilitate networking and matching mentors- mentees, the meeting phone Apps and website will list mentors and participants with well-prepared research ideas (Specific Aims) and other scientific abstracts. Two Specific Aims are Aim 1. Innovative Mentorship for Emerging Clinicians and Scientists; and Aim 2. Dissemination of Cross-Disciplinary New Knowledge and Techniques for New Collaborations and Enhanced Patient Care. A stand-alone R13 conference could be ideal but too costly for meeting space rent, audio/visual services, and support for young investigators. The R13 Conference will be strategically held immediately prior to the 50th MSTS Annual Meeting for cost reduction and improved participation from clinicians, scientists, allied health care workers, and industry R&D staffs.

Up to $20K

2027-05-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Normalized cerebrovascular reactivity MRI in small-vessel-disease (SVD) related cognitive impairment

NIA - National Institute on Aging

Project Summary/Abstract Small-vessel-disease related vascular contributions to cognitive impairment (VCI) represents a major cause of cognitive dysfunction in older individuals, as up to 80% of patients with Alzheimer’s Disease have vascular pathology. Therefore, there is a real urgency to characterize vascular pathology using biomarkers. Cerebrovascular reactivity (CVR), an index of cerebral vessel’s capacity to dilate in response to vasostimulation such as CO2 inhalation, is a highly promising biomarker in VCI. The PI is a leading expert in CVR mapping and is participating in the MarkVCID study in which CVR is one of the candidate biomarkers for VCI that are undergoing a longitudinal study in 16 sites across the U.S. However, current CVR technique is susceptible to physiological confounding factors, as the BOLD signal that is widely used as a readout of the vascular responses is known to be complex and is confounded by factors such as vessel density (more veins, more BOLD signal), imaging parameters, and hematocrit levels. The central goal of the proposed project is therefore to develop a normalized CVR mapping approach using both hypercapnia and hyperoxia challenges. Based on a rigorous theoretical model, this new technique utilizes the BOLD-reactivity of O2 to normalize the BOLD-reactivity to CO2, which eliminates the dependence of CVR on basal physiological parameters mentioned above. The proposed nCVR will have a direct relationship to cerebral blood flow (CBF), unlike the traditional BOLD-CVR. We will achieve our central goal through three Aims. Aim 1 will focus on the development of the nCVR technique and benchmark its test-retest reproducibility and sensitivity to CVR alterations. We hypothesize that the nCVR technique is superior to the existing BOLD-CVR technique in detecting a CVR reduction. Aim 2 will validate the nCVR technique with massively averaged ASL-CBF-CVR as a gold-standard. We hypothesize that the nCVR and ASL-CBF CVR maps will show highly congruent spatial features, both of which will reveal a homogeneous CVR between tissue and vessel regions, significantly enhancing the utility of CVR as a biomarker in detecting abnormalities. Finally, we will demonstrate the feasibility and diagnostic sensitivity of nCVR in vascular cognitive impairment (VCI) by applying the nCVR technique in three groups of participants, specifically Mild Cognitive Impairment (MCI) patients with high vascular risks, MCI patients with no or low vascular risks, and cognitively normal controls. We will also compare its diagnostic sensitivity to the existing BOLD-CVR method. Impact: Once these specific aims are accomplished, a new clinically practical method of CVR will have been developed, which represents a major technical innovation in CVR mapping and will significantly enhance the sensitivity of CVR as a biomarker for the diagnosis and treatment monitoring of VCI.

Up to $589K

2031-01-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Norman E. Borlaug International Agricultural Science and Technology Fellowship Program FY2026

Agriculturerural development

Foreign Agricultural Service

The U.S. Department of Agriculture, Foreign Agricultural Service, Fellowship Programs, announces this funding opportunity to support the Norman E. Borlaug International Agricultural Science and Technology Fellowship Program by issuing a new award. This opportunity is available to State cooperative institutions or other colleges and universities in the United States, as defined at 7 U.S.C. 3103. This program is intended to support applied research, extension, and education collaborations between U.S. researchers and their foreign counterparts from selected emerging market economies.Benefits to the United States: This program makes America more prosperous by strengthening trade and expanding and developing new markets with current and potential trading partners.

Up to $750K

2026-08-14

Free to search & build · $99 one-time to unlock the application pack · No subscription

North American Star Consortium

NCI - National Cancer Institute

PROJECT SUMMARY / ABSTRACT This administrative supplement request seeks continued support for the Early Therapeutics Clinical Trials Network (ETCTN) UM1 North American Star Consortium (NASC), led by the Princess Margaret Cancer Centre (LAO) with partnering Academic Organizations including the Moffitt Cancer Center (MCC), Virginia Commonwealth University (VCU), Northwestern University (NWU), the University of Texas Southwestern (UTSW), the Rutgers Cancer Institute of New Jersey (CINJ), and the Sylvester Comprehensive Cancer Center (SCCC). Due to the delayed publication of the new ETCTN Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) has advised that current UM1 sites may request a 12-month extension with funds to maintain critical clinical research operations. During the extension period, NASC will continue executing early-phase therapeutic clinical trials, supporting patient accrual, ensuring high-quality biospecimen collection for protocol-mandated analyses, and sustaining essential scientific and administrative infrastructure. This supplement will permit uninterrupted operation of ETCTN trials across NASC institutions, ensuring continuity of early-phase drug development efforts that are central to the mission of the ETCTN and aligned with the scientific scope of the parent award.

Up to $1.8M

2027-02-28

Free to search & build · $99 one-time to unlock the application pack · No subscription

North American Testis Workshop 2026

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

Project Summary This R13 application requests funds to support the XXVIIIth North American Testis Workshop “Of Flies, Mice, and Men: Novel Models that are Changing our Understanding of Testis Biology”, which will be held from April 15-18, 2026, at the Embassy Suites by Hilton Scottsdale Resort in Scottsdale, Arizona. The Workshop will be held immediately prior to the annual meeting of the American Society of Andrology at the same venue. Since 1972, the North American Testis Workshop has been the foremost international forum for both basic and clinician-scientists to present and discuss their recent findings on the development, regulation, and functions of the testis. The Workshop regularly attracts 150-200 attendees from North America and around the world. It is also an important scientific platform for the next generation of testis biologists; approximately one-third of the Workshop participants are trainees. The requested R13 funds will be used to help defray travel costs for 20 trainees and/or early-career investigators who are selected based on scientific merit of the submitted abstracts. R13 funds will also be used to offset a portion of the accommodation costs for the 15 invited speakers. The main objectives of the Workshop are: 1) to provide a platform for the dissemination and discussion of new discoveries on testis biology, especially novel data obtained using the latest omics strategies as well as new biotechnologies (single cell, gene editing) and models of study (atypical species models, artificial intelligence). By combining multiple strategies, conference participants will be provided with a more complete picture of testis biology at the cellular and molecular levels. It will also inspire and encourage translation of the new knowledge to clinical applications and accelerate drug discovery and therapeutics; (2) to create opportunities for scientific exchange and collaborations among peers to foster career growth and to ensure continued advances in the field of testis biology; (3) to offer a forum for trainees (fellows, postdocs and graduate students) and early-career investigators (within the first five years of independent research) to present their research, receive feedback from established investigators, and build professional relationships, all of which are known to be critical for intellectual, scientific, professional, and academic growth.

Up to $20K

2027-04-15

Free to search & build · $99 one-time to unlock the application pack · No subscription

North American Wetlands Conservation Act 2021-2 U.S. Standard Grants

Environmentalsustainability

Fish and Wildlife Service

The U.S. Standard Grants Program is a competitive, matching grants program that supports public-private partnerships carrying out projects in the United States that further the goals of the North American Wetlands Conservation Act. Projects must involve only long-term protection, restoration, enhancement and/or establishment of wetland and associated upland habitats to benefit migratory birds. The program requires a 1:1 non-federal match and research funding is ineligible. This program supports the DOI and FWS mission of protecting and managing the nation's natural resources by collaborating with partners and stakeholders to conserve land and water and to expand outdoor recreation and access.

$100K – $1M

rolling

Free to search & build · $99 one-time to unlock the application pack · No subscription

NORTH BENNINGTON VILLAGE OF BETTER ROADS

Transportation Agency

NORTH BENNINGTON VILLAGE OF BETTER ROADS

Up to $2K

2027-10-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

North Carolina Area Agency on Aging — Community Grants

senior servicesnutritiontransportation+1

North Carolina Area Agency on Aging

Grants from North Carolina's Area Agencies on Aging for programs serving older adults including nutrition, transportation, caregiver support, and health promotion.

$10K – $75K

2026-09-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

North Carolina Arts Council — Grant Programs

North Carolina Arts Council

North Carolina Arts Council provides grants to support arts and cultural programming, artist fellowships, arts education, and community-based arts projects across NC.

$1K – $100K

Annual

artscultureEducation

Free to search & build · $99 one-time to unlock the application pack · No subscription

North Carolina Commerce — Workforce — Workforce Development Grants

North Carolina Commerce — Workforce

North Carolina Commerce — Workforce administers workforce development grants funding job training, apprenticeships, incumbent worker training, and employer-based training programs in NC.

$10K – $500K

workforcetrainingeconomic_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

North Carolina DD Council — Community Grants

developmental disabilitiescommunity inclusionself-advocacy+1

North Carolina Council on Developmental Disabilities

Grants from the North Carolina Developmental Disabilities Council for community inclusion, self-advocacy, and systems change projects.

$10K – $75K

2026-09-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

North Carolina Department of Commerce — Small Business Grant Programs

North Carolina Department of Commerce

North Carolina Department of Commerce offers grants, incentives, and financial assistance for small businesses, startups, and economic development projects in NC.

$5K – $250K

economic_developmentsmall_business

Free to search & build · $99 one-time to unlock the application pack · No subscription

North Carolina Housing Finance Agency (NCHFA) — Housing & Community Development Grants